Abstract: The present invention provides the porphyrin compound which is used for photodynamic diagnosis and/or treatment for animals, and the photodynamic diagnostic and/or therapeutic agent for animals.

Abstract: The present invention provides the porphyrin compound having nitroimidazole in the molecule, which is used for diagnosis and/or treatment of cancer in magnetic resonance imaging (MRI) and/or radiotherapy as well as for DDS therapy. The porphyrin compound of the present invention shows no phototoxicity, and represented by the following formula: [wherein, R1 and R2 are —CH═CH2 or —CH(CH3)—OH, —CH(CH3)—O—(CH2)n—NH—Ra; R3 is hydrogen atom or —CO—(CH2)m—COOH; and M is transition metal of Mn, Fe, Co or Cu], (in which, Ra is hydrogen atom or the group represented by the following formula: n and m are the integer 2 or 3), or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides an iminochlorin aspartic acid derivative represented by the following formula (I): ##STR1## Wherein Asp represents an aspartic acid residue, or a pharmaceutically acceptable salt thereof. The compound of the present invention is useful as a photosensitizer for photophysico-chemical diagnosis and therapy of cancer, because it has a high accumulability to cancerous cells, reactivity to external energy and a cancerous cell destroying effect which is effective even against cancers developing in deep site, while it is rapidly excreted from normal cells and therefore causes no damage thereto.